hVIVO PLC (HVO)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
17.75p
Buy
18.25p
-0.125p (-0.69%)
Venn Life Sciences Holdings PLC is engaged into a Clinical Research Organisation (CRO) providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.
Prices updated at 16 May 2025, 16:43 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Most recent dividend payment
0.002 | |
Cash Dividend | |
15 May 2025 | |
10 Apr 2025 | |
16 May 2025 | |
11 Jun 2025 |
Total dividend yield
Dividend history and forecast data table
Year | Dividend per share | Dividend growth (%) |
---|---|---|
2025 | 0.0020 | - |
2024 | 0.0020 | - |
2023 | 0.0045 | - |
2022 | - | - |
2021 | - | - |
2020 | - | - |
2019 | - | - |
2018 | - | - |
2017 | - | - |
2016 | - | - |
Total dividend yield data table
Year | Dividend yield (%) | Buyback yield (%) | Total yield (%) |
---|---|---|---|
2025 | 1.05 | - | 1.05 |
2024 | 0.98 | - | 0.98 |
2023 | - | - | - |
2022 | - | - | - |
2021 | - | - | - |
2020 | - | - | - |
2019 | - | - | - |
2018 | - | - | - |
2017 | - | - | - |
2016 | - | - | - |
Dividend per share
% of earnings paid to shareholders
Dividend per share data table
Year | Dividend per share |
---|---|
2025 | 0.0020 |
2024 | 0.0020 |
2023 | 0.0045 |
2022 | - |
2021 | - |
2020 | - |
2019 | - |
2018 | - |
2017 | - |
2016 | - |
% of earnings paid to shareholders data table
Year | Payout ratio (%) |
---|---|
2025 | 12.90 |
2024 | 7.91 |
2023 | - |
2022 | - |
2021 | - |
2020 | - |
2019 | - |
2018 | - |
2017 | - |
2016 | - |
Latest Financial Report as of 16 May 2025
Dividend amount and dividend per share are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns.